Cargando…
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
PURPOSE: To review the response and outcomes of (177)Lu-DOTA-octreotate chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) expressing high levels of somatostatin receptors with uncontrolled symptoms or disease progression. METHODS: A total of 68 patients (39 men; 1...
Autores principales: | Kong, G., Thompson, M., Collins, M., Herschtal, A., Hofman, M. S., Johnston, V., Eu, P., Michael, M., Hicks, Rodney J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159597/ https://www.ncbi.nlm.nih.gov/pubmed/24844348 http://dx.doi.org/10.1007/s00259-014-2788-5 |
Ejemplares similares
-
Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival
por: Levy, Sonja, et al.
Publicado: (2020) -
Changes in biodistribution on (68)Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
por: Cherk, Martin H., et al.
Publicado: (2018) -
The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with (177)Lu DOTATATE (LuTate)
por: Alipour, R., et al.
Publicado: (2023) -
Lutetium-labelled peptides for therapy of neuroendocrine tumours
por: Kam, B. L. R., et al.
Publicado: (2012) -
CT/MRI of neuroendocrine tumours
por: Reznek, Rodney H
Publicado: (2006)